Aankondiging • Jun 28
Dermapharm Holding Se Confirms Earnings Guidance for 2026 Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million. Upcoming Dividend • Jun 22
Upcoming dividend of €0.88 per share Eligible shareholders must have bought the stock before 29 June 2026. Payment date: 01 July 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%). Aankondiging • May 19
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time. Recent Insider Transactions • May 18
Chairman of the Supervisory Board recently bought €833m worth of stock On the 14th of May, Wilhelm Beier bought around 18m shares on-market at roughly €46.83 per share. This transaction increased Wilhelm's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wilhelm has been a buyer over the last 12 months, purchasing a net total of €955m worth in shares. Price Target Changed • May 14
Price target increased by 10% to €47.88 Up from €43.50, the current price target is an average from 4 analysts. New target price is 5.2% below last closing price of €50.50. Stock is up 42% over the past year. The company is forecast to post earnings per share of €2.69 for next year compared to €2.46 last year. Live-nieuws • May 14
Dermapharm Holding Q1 Branded Pharma Growth Drives Strong Cash Flow and Guidance Confirmation Dermapharm Holding SE reported solid Q1 2026 results, with revenue and adjusted EBITDA growth supported mainly by a 12% increase in its Branded Pharmaceuticals segment, helped by organic growth and the Mucos Group and F. Trenka acquisitions.
Free cash flow in the quarter was significantly higher, while segments affected by reduced parallel imports and other healthcare products saw weaker contributions in line with prior portfolio shifts.
The company continued integrating the Mucos Group and completed a share buyback program that lowered its free float to just above 10%, and the Board of Management confirmed its full-year 2026 guidance for revenue, EBITDA, margins and cash flow.
The mix of Branded Pharmaceuticals expansion, higher free cash flow and confirmation of full-year guidance indicates a business model currently supported by higher-margin products and active portfolio management.
A free float just above 10% can tighten trading liquidity, so you may want to factor in potential liquidity constraints and ownership concentration when assessing position size and time horizon. Declared Dividend • Apr 02
Dividend reduced to €0.88 Dividend of €0.88 is 2.2% lower than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (29% cash payout ratio). The dividend has increased by an average of 2.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Apr 01
Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026 Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Aankondiging • Mar 11
Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million. Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026. Price Target Changed • Nov 21
Price target decreased by 11% to €42.00 Down from €47.00, the current price target is an average from 5 analysts. New target price is 20% above last closing price of €35.10. Stock is down 6.4% over the past year. The company is forecast to post earnings per share of €2.28 for next year compared to €2.11 last year. Reported Earnings • Nov 14
Third quarter 2025 earnings released: EPS: €0.76 (vs €0.60 in 3Q 2024) Third quarter 2025 results: EPS: €0.76 (up from €0.60 in 3Q 2024). Revenue: €312.6m (flat on 3Q 2024). Net income: €41.2m (up 27% from 3Q 2024). Profit margin: 13% (up from 10% in 3Q 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. New Risk • Sep 01
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 137% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (137% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: €0.39 (vs €0.32 in 2Q 2024) Second quarter 2025 results: EPS: €0.39 (up from €0.32 in 2Q 2024). Revenue: €280.8m (down 1.0% from 2Q 2024). Net income: €20.9m (up 21% from 2Q 2024). Profit margin: 7.4% (up from 6.1% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Jul 09
Chairman of the Supervisory Board recently bought €122m worth of stock On the 3rd of July, Wilhelm Beier bought around 3m shares on-market at roughly €34.94 per share. This transaction increased Wilhelm's direct individual holding by 22x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Wilhelm's only on-market trade for the last 12 months. Aankondiging • Jun 28
Dermapharm Holding SE Approves Annual Dividend Dermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution. Upcoming Dividend • Jun 20
Upcoming dividend of €0.90 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.5%). New Risk • May 23
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Aankondiging • May 16
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • May 16
First quarter 2025 earnings released: EPS: €0.62 (vs €0.81 in 1Q 2024) First quarter 2025 results: EPS: €0.62 (down from €0.81 in 1Q 2024). Revenue: €310.5m (up 3.0% from 1Q 2024). Net income: €33.4m (down 23% from 1Q 2024). Profit margin: 11% (down from 14% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 03
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: EPS: €2.11 (up from €1.16 in FY 2023). Revenue: €1.20b (up 3.9% from FY 2023). Net income: €113.8m (up 82% from FY 2023). Profit margin: 9.5% (up from 5.4% in FY 2023). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Price Target Changed • Apr 02
Price target increased by 8.9% to €52.80 Up from €48.49, the current price target is an average from 5 analysts. New target price is 44% above last closing price of €36.75. Stock is up 16% over the past year. The company is forecast to post earnings per share of €2.10 for next year compared to €1.16 last year. Declared Dividend • Mar 17
Dividend of €0.90 announced Shareholders will receive a dividend of €0.90. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 2.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (52% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 2.3% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 39% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Jan 02
Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025 Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025 Reported Earnings • Nov 17
Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023) Third quarter 2024 results: EPS: €0.60 (up from €0.46 in 3Q 2023). Revenue: €337.1m (up 17% from 3Q 2023). Net income: €32.4m (up 30% from 3Q 2023). Profit margin: 9.6% (up from 8.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023) Second quarter 2024 results: EPS: €0.32 (up from €0.17 loss in 2Q 2023). Revenue: €292.6m (up 9.8% from 2Q 2023). Net income: €17.3m (up €26.5m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 25% per year. Price Target Changed • Jun 25
Price target decreased by 12% to €50.13 Down from €56.90, the current price target is an average from 4 analysts. New target price is 40% above last closing price of €35.70. Stock is down 19% over the past year. The company is forecast to post earnings per share of €1.90 for next year compared to €1.16 last year. New Risk • May 19
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.0% net profit margin). Reported Earnings • May 19
First quarter 2024 earnings released: EPS: €0.81 (vs €0.92 in 1Q 2023) First quarter 2024 results: EPS: €0.81 (down from €0.92 in 1Q 2023). Revenue: €309.7m (down 4.1% from 1Q 2023). Net income: €43.6m (down 12% from 1Q 2023). Profit margin: 14% (down from 15% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year. Aankondiging • May 09
Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024 Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024 Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022) Full year 2023 results: EPS: €1.16 (down from €2.49 in FY 2022). Revenue: €1.19b (up 15% from FY 2022). Net income: €62.4m (down 54% from FY 2022). Profit margin: 5.2% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Aankondiging • Mar 28
Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024 Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024. Declared Dividend • Mar 17
Dividend of €0.88 announced Shareholders will receive a dividend of €0.88. Ex-date: 6th June 2024 Payment date: 10th June 2024 Dividend yield will be 2.4%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Mar 14
Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024 Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024 New Risk • Nov 19
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 180% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (180% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.1% net profit margin). Reported Earnings • Nov 17
Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022) Third quarter 2023 results: EPS: €0.46 (down from €0.98 in 3Q 2022). Revenue: €307.9m (up 16% from 3Q 2022). Net income: €24.8m (down 53% from 3Q 2022). Profit margin: 8.1% (down from 20% in 3Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 30
Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022) Second quarter 2023 results: €0.17 loss per share (down from €0.27 profit in 2Q 2022). Revenue: €269.1m (up 11% from 2Q 2022). Net loss: €9.19m (down 163% from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 08
Upcoming dividend of €1.05 per share at 2.3% yield Eligible shareholders must have bought the stock before 15 June 2023. Payment date: 19 June 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.6%). Major Estimate Revision • May 04
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €1.14b to €1.11b. EPS estimate also fell from €2.96 per share to €2.61 per share. Net income forecast to grow 4.5% next year vs 3.9% growth forecast for Pharmaceuticals industry in Germany. Consensus price target broadly unchanged at €57.00. Share price was steady at €44.00 over the past week. Major Estimate Revision • Apr 27
Consensus EPS estimates increase by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €1.11b to €1.14b. EPS estimate increased from €2.59 to €2.96 per share. Net income forecast to grow 19% next year vs 5.5% growth forecast for Pharmaceuticals industry in Germany. Consensus price target of €56.00 unchanged from last update. Share price fell 2.7% to €44.68 over the past week. Major Estimate Revision • Apr 25
Consensus EPS estimates increase by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €1.11b to €1.14b. EPS estimate increased from €2.59 to €2.96 per share. Net income forecast to grow 19% next year vs 5.6% growth forecast for Pharmaceuticals industry in Germany. Consensus price target of €56.00 unchanged from last update. Share price rose 5.0% to €46.00 over the past week. Reported Earnings • Mar 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 15
Price target decreased by 9.9% to €56.40 Down from €62.60, the current price target is an average from 5 analysts. New target price is 53% above last closing price of €36.80. Stock is down 40% over the past year. The company is forecast to post earnings per share of €3.58 for next year compared to €3.89 last year. Price Target Changed • Jan 06
Price target decreased to €60.60 Down from €65.33, the current price target is an average from 5 analysts. New target price is 65% above last closing price of €36.62. Stock is down 53% over the past year. The company is forecast to post earnings per share of €3.42 for next year compared to €3.89 last year. Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021) Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target decreased to €64.60 Down from €69.60, the current price target is an average from 4 analysts. New target price is 45% above last closing price of €44.50. Stock is down 43% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €3.89 last year. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €37.54, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 24% over the past three years. Reported Earnings • Sep 09
Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021) Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Aankondiging • Sep 09
Dermapharm Holding SE Announces Executive Changes Dermapharm Holding SE announced that Hilde Neumeyer has left the company. She will be succeeded as Chief Financial Officer by Christof Dreibholz (55) on 1 November 2022. As an auditor and tax consultant, Mr. Dreibholz has many years of experience in the areas of finance, controlling and accounting. Mr. Dreibholz has been employed by Deloitte since 2002 and has been responsible for the implementation of financial due diligence projects as a partner since 2008. Mr. Dreibholz has advised the Dermapharm Group on numerous national and international acquisitions and therefore knows the structures of the Dermapharm Group very well. Upcoming Dividend • May 26
Upcoming dividend of €2.17 per share Eligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.5%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (2.6%). Reported Earnings • May 19
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the next year, revenue is forecast to grow 7.8%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Aankondiging • May 19
Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022 Dermapharm Holding SE provided earnings guidance for the full year 2022. For the year, the company expected growth in consolidated revenue by 10% to 13% (2021: EUR 942.9 million) and in consolidated EBITDA by 3% to 7% (EUR 351.1 million). Reported Earnings • Apr 14
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Over the next year, revenue is forecast to grow 10%, compared to a 7.9% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Aankondiging • Apr 12
Dermapharm Holding SE Re-Affirm Earnings Guidance for the Year 2022 Dermapharm Holding SE announced the Board of Management confirms the guidance published on 29 March 2022 and expects consolidated revenue to grow by 10% to 13% and consolidated EBITDA by 3% to 7% in 2022. Aankondiging • Feb 02
Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED). Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) for approximately €120 million on December 15, 2021. An upfront payment of €80 million, subject to customary cash and debt adjustments, will be made upon the closing of the transaction in addition to an earnout payment of up to €42.6 million subject to the achievement of select milestones by the C³ business. As part of the agreement, all C³ employees will be retained by Dermapharm following the closing of the transaction. Assuming timely receipt of required regulatory approvals and satisfaction of other closing conditions, the transaction is expected to close by January 31, 2022.
Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED) on January 31, 2022. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €74.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 251% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €118 per share. Price Target Changed • Jan 05
Price target increased to €102 Up from €95.17, the current price target is an average from 6 analysts. New target price is 30% above last closing price of €78.50. Stock is up 37% over the past year. The company is forecast to post earnings per share of €3.60 for next year compared to €1.59 last year. Major Estimate Revision • Dec 22
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate increased from €3.33 to €3.70. Revenue forecast steady at €951.0m. Net income forecast to grow 30% next year vs 11% growth forecast for Pharmaceuticals industry in Germany. Consensus price target up from €93.90 to €98.50. Share price rose 6.1% to €87.10 over the past week. Price Target Changed • Dec 17
Price target increased to €98.50 Up from €92.00, the current price target is an average from 6 analysts. New target price is 15% above last closing price of €85.50. Stock is up 53% over the past year. The company is forecast to post earnings per share of €3.33 for next year compared to €1.59 last year. Aankondiging • Dec 16
Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million. Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million on December 15, 2021. The consideration consists of an upfront payment of €80 million, subject to customary cash and debt adjustments, which will be made upon the closing of the transaction in addition to an earnout payment of up to €42.6 million subject to the achievement of select milestones by the C3 - Cannabionoid Compound business. All C3 - Cannabionoid Compound Company employees will be retained by Dermapharm. The transaction is subject to regulatory approvals and satisfaction of other closing conditions. The transaction is expected to close by January 31, 2022.